Quince Therapeutics, Inc. has discontinued clinical development of its lead investigational therapy, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), following the failure of its pivotal Phase 3 NEAT trial in Ataxia-Telangiectasia (A-T) to meet both primary and secondary endpoints. The U.S.-based biotechnology company will now pivot toward preserving cash reserves and exploring alternative strategic options.

The company disclosed that the trial’s primary endpoint—change in RmICARS score at six months—failed to achieve statistical significance, with placebo outperforming the active treatment arm. This surprising reversal, combined with a lack of signal in the Clinical Global Impression of Severity (CGI-S) secondary endpoint, leaves Quince with no viable regulatory path for eDSP in its current form.

What the NEAT trial failure reveals about the limits of red blood cell–based corticosteroid delivery in neurodegeneration

The most immediate implication of the NEAT outcome is a hard reset on the therapeutic promise of red blood cell–encapsulated dexamethasone in complex neurodegenerative conditions. Quince’s AIDE (Autologous Intracellular Drug Encapsulation) platform was built on the premise that encapsulating corticosteroids within autologous erythrocytes could mitigate chronic-use toxicity while extending therapeutic efficacy. That premise remains intact in theory, but NEAT has tested it in practice—and found it wanting.

The failure to separate from placebo on the RmICARS scale suggests that either the underlying anti-inflammatory mechanism is not relevant enough to disease modification in A-T, or that even with improved tolerability, the dosing, biodistribution, or timing was insufficient to impact clinical progression.

Neurologists and industry analysts tracking A-T trials note that disease heterogeneity and the slow progression curve—especially over six months—make it notoriously difficult to capture changes that are both statistically and clinically meaningful. The fact that placebo showed numerically greater improvement also introduces the possibility that behavioral, caregiver, or functional biases influenced outcome perception.

This is not an uncommon issue in rare neurodevelopmental trials, where even highly structured rating scales struggle to filter out placebo drift or capture small but meaningful quality-of-life gains. However, Quince’s high reliance on a single mechanism and single platform asset left it especially vulnerable to a trial miss of this nature.

A once-promising rare disease pipeline enters stasis amid strategic uncertainty

Quince Therapeutics’ pipeline has now lost its primary clinical driver. With eDSP discontinued, the company no longer has a late-stage program in development. While the firm retains its AIDE platform and associated manufacturing infrastructure, it lacks another disclosed investigational drug currently ready for Phase 2 or 3 initiation.

As a result, the company is transitioning into capital preservation mode—a common outcome in rare disease biotech when pivotal trials fail. Investors and strategic watchers will be looking closely at whether Quince seeks to partner its AIDE platform, restructure into a contract development and manufacturing organization (CDMO), or pursue a merger or asset sale.

The biotech industry is replete with examples of platform-oriented firms pivoting to service or royalty-based models post-failure, but the viability of such a transition depends on whether AIDE can demonstrate value beyond corticosteroids or in indications with faster response readouts. Absent a new lead program or compelling non-clinical data package, Quince may struggle to attract partners without significant dilution or asset divestiture.

Clinical trial design scrutiny intensifies in light of NEAT’s failed primary and secondary endpoints

The NEAT trial was robustly designed by rare disease standards, enrolling 105 participants across the United States, the United Kingdom, and Europe. The primary analysis population consisted of children aged six to nine—an age group selected for its expected rate of neurological progression. Yet the use of RmICARS, a refined version of the ICARS scale with higher sensitivity in posture and gait, proved insufficient in detecting a clear drug effect.

The mean change in RmICARS was 0.94 in the eDSP arm versus 2.24 in placebo, with a p-value of 0.0851. Although nearing significance, the directionality of the results is deeply problematic, especially given the double-blind, placebo-controlled nature of the trial. Similarly, the CGI-S score—commonly used as a clinician-rated global assessment—also showed no benefit with treatment.

Clinical trialists have pointed out that ultra-rare pediatric neurodegenerative disorders pose significant measurement and statistical design challenges. Heterogeneity in symptom onset, caregiver engagement, and natural history progression make six-month trials difficult to interpret without highly sensitive digital endpoints or biomarker integration. In NEAT’s case, the absence of biomarker corroboration left the trial reliant on functional and observer-based scores, increasing susceptibility to noise.

It is also worth noting that the study used six eDSP infusions over a 6-month period, spaced 21 to 30 days apart. Whether this frequency was sufficient to sustain intra-erythrocyte corticosteroid levels at therapeutic thresholds remains unclear. The company has not disclosed pharmacodynamic or pharmacokinetic subanalyses that could help explain the disconnect between mechanism and efficacy.

Despite clean safety data, the platform’s clinical value proposition weakens

Notably, eDSP was well tolerated, with no major safety flags. The most commonly reported adverse events were pruritis and pyrexia, and no treatment-related serious adverse events were reported. This supports the premise that red blood cell–based delivery can indeed reduce systemic corticosteroid exposure and toxicity.

However, a clean safety profile without efficacy is not sufficient to sustain development, particularly in a condition like A-T where the burden of progression is high, and the regulatory bar for approval—especially under accelerated pathways—is rising. Regulators in both the United States and Europe are increasingly requiring clear evidence of functional improvement or durable disease modification, not just tolerability or biomarker shifts.

In this context, eDSP’s inability to demonstrate superiority to placebo undercuts the broader commercial and regulatory case for AIDE. Unless the platform can now show differentiated results in a new indication, the clinical rationale for red blood cell–based chronic delivery will remain in question.

Ataxia-Telangiectasia remains an untreated frontier with high unmet need

A-T is one of the most debilitating and fatal inherited neurodegenerative disorders diagnosed in early childhood. Characterized by progressive ataxia, immunodeficiency, respiratory complications, and high cancer risk, the disease typically leads to wheelchair dependence in adolescence and premature death in early adulthood.

Globally, there are no approved pharmacologic therapies for A-T. Supportive care, physical therapy, and infection management remain the mainstay of treatment. Investigational efforts in the past have included small molecule anti-inflammatories, gene therapy approaches targeting ATM mutations, and immune modulation strategies, but none have advanced to global regulatory approval.

Quince’s eDSP program was one of the few industry-sponsored late-stage efforts in this space, making its failure particularly disappointing for the rare disease community. While several academic groups continue to pursue gene editing and mRNA approaches, these remain in preclinical or early clinical stages. The lack of a validated biomarker or imaging correlate for progression further complicates clinical development.

What industry observers are watching next: platform salvage, pivot options, and partner appetite

With eDSP shelved, all eyes are now on whether Quince Therapeutics can reposition AIDE as a platform asset rather than a failed therapeutic concept. Several strategic pathways exist, including repurposing the red blood cell–based encapsulation system for short-acting oncology payloads, inflammatory conditions with rapid-onset markers, or even gene therapy vector delivery.

Another option is to license out the encapsulation technology to CDMOs or mid-sized firms looking to extend the life of toxic drugs facing formulation challenges. However, this depends on whether Quince has sufficient intellectual property protection, automation scalability, and reproducibility to meet GMP expectations in non-rare indications.

From an investor standpoint, Quince’s next moves will need to signal platform validation beyond rhetoric. Releasing detailed subgroup analyses, PK/PD modeling, or plans for investigator-initiated studies could help regain some credibility. Failing that, merger, acquisition, or dissolution becomes more likely.

  Ataxia-Telangiectasia, corticosteroid delivery, dexamethasone sodium phosphate, eDSP, NEAT trial, pediatric neurodegeneration, Quince Therapeutics, rare disease, red blood cell drug delivery